Larimar Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Larimar Therapeutics sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
Larimar Therapeutics: 7 sponsored US clinical trials, 1 recruiting.
Larimar Therapeutics sponsors 7 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 5 completed. 0 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Friedreich Ataxia, with 1 trials.
Upper-quartile sponsor footprint
Larimar Therapeutics sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
7 total, page 1 of 1
An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia
NCT06447025
A Study to Assess Nomlabofusp in Adolescents and Children With Friedreich's Ataxia
NCT06681766
A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia
NCT05579691
Determine Range of Tissue Frataxin Concentrations and Other Potential Biomarkers
NCT05028764
Multiple Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia
NCT04519567
A Study to Assess Variation in Potential Biomarkers in Friedreich Ataxia
NCT04255680
Single Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia
NCT04176991
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 2 |
Therapeutic Areas
What is open in the Larimar Therapeutics pipeline
1 recruiting of 7 indexed (14% open); 5 completed (71%).
Phase mix: 0 late (III/IV) vs 5 early (I/II) (early-phase heavy).
Top condition: Friedreich Ataxia (1 trial), 0 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Larimar Therapeutics: open-pipeline peers nationwide
Peers matched on 7 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
Larimar Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 trials (± recruiting share)
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors near 14% open enrollment (± trial volume)
- Academic and Community Cancer Research United · 14% recruiting · 42 trials
- Adaptive Biotechnologies · 14% recruiting · 7 trials
- AgelessRx · 14% recruiting · 7 trials
- Alaska Blind Child Discovery · 14% recruiting · 7 trials
Related
What to do with this Larimar Therapeutics page
7 registered trials is a research-attention snapshot, not an endorsement of Larimar Therapeutics or any single study.
- 1 of Larimar Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Friedreich Ataxia is the condition Larimar Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Friedreich Ataxia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Larimar Therapeutics pipeline card: 7 registered trials from official public datasets.Report a data error.